Evidence map›Paper›PMID 32047132›Full record

ArticlemBio2020

Hijacking the Fusion Complex of Human Parainfluenza Virus as an Antiviral Strategy.

T C Marcink, E Yariv, K Rybkina, V Más, F T Bovier, A des Georges, A L Greninger, C A Alabi, M Porotto, N Ben-Tal and 1 more

Abstract read
In one paragraph

Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Antivirals targeting paramyxovirus membrane fusion.Current opinion in virology · 2021
    Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

T C Marcink *Department of Pediatrics, Columbia University Medical Center, New York, New York, USA.
E Yariv *Department of Biochemistry and Molecular Biology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
K Rybkina *Department of Pediatrics, Columbia University Medical Center, New York, New York, USA.
V MásCentro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
F T BovierDepartment of Pediatrics, Columbia University Medical Center, New York, New York, USA.
A des GeorgesDepartment of Chemistry and Biochemistry, Advanced Science Research Center, City College of New York, New York, New York, USA.
A L GreningerDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
C A AlabiRobert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York, USA.
M PorottoDepartment of Pediatrics, Columbia University Medical Center, New York, New York, USA.
N Ben-TalDepartment of Biochemistry and Molecular Biology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel bental@tauex.tau.ac.il Anm2047@gmail.com.
A MosconaDepartment of Pediatrics, Columbia University Medical Center, New York, New York, USA bental@tauex.tau.ac.il Anm2047@gmail.com.

Funding

Molecular basis for paramyxovirus entryR01AI031971 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCONA, ANNE · 1998 to 2016
$6.6M
Engineering protease-resistant alpha-beta peptides for broad-spectrum antiviralsR01AI114736 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCONA, ANNE · 2015 to 2019
$3.7M
NIAID NIH HHS R01 AI031971NIAID NIH HHS R01 AI114736
6 · The paper itself

Abstract

The receptor binding protein of parainfluenza virus, hemagglutinin-neuraminidase (HN), is responsible for actively triggering the viral fusion protein (F) to undergo a conformational change leading to insertion into the target cell and fusion of the virus with the target cell membrane. For proper viral entry to occur, this process must occur when HN is engaged with host cell receptors at the cell surface. It is possible to interfere with this process through premature activation of the F protein, distant from the target cell receptor. Conformational changes in the F protein and adoption of the postfusion form of the protein prior to receptor engagement of HN at the host cell membrane inactivate the virus. We previously identified small molecules that interact with HN and induce it to activate F in an untimely fashion, validating a new antiviral strategy. To obtain highly active pretriggering candidate molecules we carried out a virtual modeling screen for molecules that interact with sialic acid binding site II on HN, which we propose to be the site responsible for activating F. To directly assess the mechanism of action of one such highly effective new premature activating compound, PAC-3066, we use cryo-electron tomography on authentic intact viral particles for the first time to examine the effects of PAC-3066 treatment on the conformation of the viral F protein. We present the first direct observation of the conformational rearrangement induced in the viral F protein.

Indexed as

Antiviral AgentsCell Culture TechniquesCell LineDrug DiscoveryEpithelial CellsHigh-Throughput Screening AssaysHN ProteinHumansMolecular Docking SimulationParainfluenza Virus 3, HumanParamyxoviridae InfectionsProtein BindingSmall Molecule LibrariesViral Fusion ProteinsVirus InternalizationAntiviral AgentsHN ProteinSmall Molecule LibrariesViral Fusion Proteinsantiviral agentscryo-electron tomographyviral fusion proteinviral protein structureviral receptor

Identifiers

PMID32047132
PMCPMC7018645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.